Beta-2 adrenergic receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Beta-2 adrenergic receptor as ChEMBL target CHEMBL5414, mapped to UniProt Q8K4Z4. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Beta-2 adrenergic receptor matters
Beta-2 adrenergic receptor is reviewed as Beta-2 adrenergic receptor (UniProt Q8K4Z4); the current evidence base includes 26 approved drugs, 759 compounds, and 182 assays, with lead potency reaching pChEMBL 10.9.
Beta-2 adrenergic receptor Sequence length is 418 aa.
Review this target as Beta-2 adrenergic receptor, mapped to UniProt Q8K4Z4. Sequence length is 418 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 26 approved drugs, 759 compounds, and 182 assays for this target. The dominant activity type is KD. CHEMBL5557828 is the current potency anchor at pChEMBL 10.9.
Use CHEMBL5557828 as the tractability anchor when discussing potency (pChEMBL 10.9).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Beta-2 adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q8K4Z4, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5557828
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL5505816
|
10.6 | IC50 | — |
|
|
No preferred name
CHEMBL1682213
|
10.3 | EC50 | — |
|
|
No preferred name
CHEMBL1940832
|
10.3 | EC50 | Clinical |
|
|
No preferred name
CHEMBL6067687
|
10.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
INDACATEROL
CHEMBL1095777
|
2009 |
|
|
ARFORMOTEROL
CHEMBL1363
|
2006 |
|
|
ARFORMOTEROL TARTRATE
CHEMBL1951071
|
2006 |
|
|
DARIFENACIN
CHEMBL1346
|
2004 |
|
|
FORMOTEROL
CHEMBL1256786
|
2001 |
|
|
SALMETEROL
CHEMBL1263
|
1994 |
|
|
BETAXOLOL
CHEMBL423
|
1985 |
|
|
LABETALOL
CHEMBL429
|
1984 |
|
|
ALBUTEROL
CHEMBL714
|
1981 |
|
|
TIMOLOL
CHEMBL499
|
1978 |
|
|
METOPROLOL
CHEMBL13
|
1978 |
|
|
PROPRANOLOL
CHEMBL27
|
1967 |
|
|
EPINEPHRINE
CHEMBL679
|
1965 |
|
|
ISOPROTERENOL
CHEMBL434
|
1956 |
|
|
NOREPINEPHRINE
CHEMBL1437
|
1950 |
|
|
FENOTEROL
CHEMBL32800
|
— |